Key facts
- Kadance’s last known valuation is $20.0M (Dec 2024).
- It has raised $9.9M; the latest was Later Stage VC in Apr 2026.
- Notable investors include American Family Ventures, Nassau ReImagine, Oncology Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Kadance
- ·The full record, as it builds
Funding rounds
No funding rounds for Kadance are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kadance
Provider of precision health management services intended to offer insights into genetic risks and personalized medical guidance. The company offers genetic testing, medication response analysis, and ongoing health support programs, enabling patients and healthcare providers to make informed decisions and manage long-term health outcomes.
- Sector
- Healthcare
- HQ
- Huntsville, AL, United States
- Founded
- 2021
- Employees
- 19
- Website
- kadance.com/
- Ownership
- Privately Held (backing)
Kadance doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kadance shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kadance in its N-PORT filings yet. We sweep new filings monthly.